Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, suggests how treatment can be optimized at induction to achieve the best possible outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL), and explains the importance of optimizing treatment early. Dr Rau also explains that patients in the relapsed/refractory setting who don’t respond to chemotherapy may benefit from an earlier introduction of bispecific T-cell engagers (BiTEs) such as blinatumomab. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.